{
    "Trade/Device Name(s)": [
        "EliA Rib-P"
    ],
    "Submitter Information": "Phadia AB",
    "510(k) Number": "K202540",
    "Predicate Device Reference 510(k) Number(s)": [
        "K981237"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MQA"
    ],
    "Summary Letter Date": "September 13, 2021",
    "Summary Letter Received Date": "September 2, 2020",
    "Submission Date": "September 1, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear Antibody Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "IgG autoantibodies specific to Rib-P proteins"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Phadia 250",
        "Phadia 2500",
        "Phadia 5000"
    ],
    "Method(s)/Technology(ies)": [
        "Solid phase fluoroenzymeimmunoassay",
        "Fluorescence immunoassay"
    ],
    "Methodologies": [
        "Semi-quantitative antibody detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "System",
        "Reagent",
        "Calibrator",
        "Control",
        "Platform"
    ],
    "Document Summary": "FDA 510(k) summary for EliA Rib-P immunoassay for semi-quantitative measurement of anti-Rib-P antibodies in human serum to aid diagnosis of systemic lupus erythematosus",
    "Indications for Use Summary": "In vitro semi-quantitative measurement of IgG antibodies to Rib-P in human serum as an aid in diagnosis of systemic lupus erythematosus (SLE) in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}